NASDAQ · HOLX
Healthcare · Medical - Instruments & Supplies
$76.01
Up+$0.00 (+0.00%)
Updated Aug 31, 2026, 10:42 AM
SID Score
6.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
HOLX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning HOLX.
HOLX research
Company profile and research snapshot.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 12, 2026 | Argus Research | Hold | — |
| Jan 5, 2026 | Evercore ISI Group | In-Line | — |
| Nov 11, 2025 | Morgan Stanley | Equal-Weight | — |
| Oct 23, 2025 | Mizuho | Neutral | — |
| Oct 22, 2025 | Stephens & Co. | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Feb 26, 2026
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported revenue of US$6.12 million for the six months to December 31, 2025 (1H FY26), down slightly from US$6.31 million a year earlier, as the company progressed multiple FebriDx commercial and regulatory milestones in the US. Product...
Yahoo · Feb 26, 2026
GE HealthCare is gaining ground with strong backlog, AI-driven imaging advances and rising service capture, while Hologic's buyout caps near-term upside.
Yahoo · Feb 24, 2026
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Yahoo · Feb 19, 2026
The business, known as DePuy Synthes, could be valued at more than $20 billion in a sale, the people said, asking not to be identified discussing confidential information. J&J is assembling documents and financials for DePuy Synthes before it meets with possible buyers in the coming weeks, the people said. Several large private equity firms are considering teaming up to potentially buy out the unit, they said.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HOLX.
